Work

Rapid high‐dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma

Year: 2024

Type: article

Abstract: Patients with relapsed/refractory multiple myeloma proceeding with chimeric antigen receptor (CAR) T-cell therapy or bispecific antibodies (BsAb) may need bridging therapy to realize their benefits. We evaluated the efficacy and safety of rapid, peripheral, high-dose cyclophosphamide (TurboCy) in 15 patients intending to proceed with CAR T-cell therapy, BsAbs, or long-term regimens. The overall response rate was 80% and the clinical benefit rate was 100% in a heavily pretreated high-risk cohort. Cytopenias were common but no deaths occurred during bridging. All patients proceeded to their next line of intended therapy. TurboCy is an effective and safe bridging strategy.

Source: eJHaem

DOI: 10.1002/jha2.1039

Authors: Marcus Marable, Kaitlin Kelly, Jennifer H. Cooperrider, Andrzej Jakubowiak, Benjamin A. Derman

Institution: University of Chicago

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,600